PHARMAC confirms access criteria for COVID-19 treatments


26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with imdevimab (branded as Ronapreve). 

Both will be available for use in DHB hospitals from 1 February 2022.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder